Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology

R Tonge1, J Shaw, B Middleton

  • 1Proteomics Group, Enabling Science and Technology (Biology), CTL, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 7TG, UK. robert.tonge@astrazeneca.com

Proteomics
|October 30, 2001
PubMed